FRMD6 and glioblastoma: The results confirmed that increased expression of FRMD6 reduces levels of phosphorylated/activated Met and PDGFRα/β in the GBM cells (Figure 7A–7B), suggesting that FRMD6 exerts its anti-GBM effect through or partially through inhibiting c-Met and/or PDGFR activity.